CD28

Last updated
CD28
CD28 structure.gif
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases CD28 , Tp44, CD28 molecule
External IDs OMIM: 186760 MGI: 88327 HomoloGene: 4473 GeneCards: CD28
Orthologs
SpeciesHumanMouse
Entrez

940

12487

Ensembl

ENSG00000178562

ENSMUSG00000026012

UniProt

P10747

P31041

RefSeq (mRNA)

NM_001243077
NM_001243078
NM_006139

NM_007642

RefSeq (protein)

NP_001230006
NP_001230007
NP_006130

NP_031668

Location (UCSC) Chr 2: 203.71 – 203.74 Mb Chr 1: 60.76 – 60.81 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. T cell stimulation through CD28 in addition to the T-cell receptor (TCR) can provide a potent signal for the production of various interleukins (IL-6 in particular).

Contents

CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins. When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen-presenting cells (APCs). The CD86 expression on antigen-presenting cells is constitutive (expression is independent of environmental factors).

CD28 is the only B7 receptor constitutively expressed on naive T cells. Association of the TCR of a naive T cell with MHC:antigen complex without CD28:B7 interaction results in a T cell that is anergic.

Furthermore, CD28 was also identified on bone marrow stromal cells, plasma cells, neutrophils and eosinophils, but the functional importance of CD28 on these cells is not completely understood. [5] [6] [7] [8] It is generally reported, that CD28 is expressed on 50% of CD8+ T cells and more than 80% CD4+ T cells in human, but during the course of activation some T cells lose this molecule. Some antigen-experienced T cells lose CD28 and subsequently can be re-activated without CD28 engagement. These CD28− T cells have generally been characterized as antigen specific and terminally differentiated, and are often described as being memory T cells (TMs). In addition, the level of positive CD28 decreases with age. [9]

As a homodimer of two chains with Ig domains, CD28 binds B7 molecules on APCs and can promote T cells proliferation and differentiation, stimulate production of growth factor, and induces the expression of anti-apoptotic proteins. [10] According to several studies, after birth, all human cells express CD28. However, in adults, 20-30% of CD8+ T cells lose CD28 expression, whereas in the elderly (+80 years) up to 50-60% of CD8+ cells lose the ability to express CD28. [11] But these statements only suggest that loss of CD28 expression marks functional differentiation to cytotoxic memory cells within clonal expansions. [12]

In general, CD28 is a primary costimulatory molecule for T cell activation, but effective co-stimulation is essential only for some T cell activation. In this case, in the absence of co-stimulatory signals, the interaction of dendritic and T cells leads to T cell anergy. The importance of the costimulatory pathway is emphasized by the fact that antagonists of co-stimulatory molecules disrupt the immune responses both in vitro and in vivo. [13] But as mentioned earlier, during the course of activation e.g. TMs lose this molecule and assume a CD28-independent existence. [14]

Signaling

CD28 possesses an intracellular domain with several residues that are critical for its effective signaling. The YMNM motif beginning at tyrosine 170 in particular is critical for the recruitment of SH2-domain containing proteins, especially PI3K, [15] Grb2 [16] and Gads. The Y170 residue is important for the induction of Bcl-xL via mTOR and enhancement of IL-2 transcription via PKCθ, but has no effect on proliferation and results a slight reduction in IL-2 production. The N172 residue (as part of the YMNM) is important for the binding of Grb2 and Gads and seems to be able to induce IL-2 mRNA stability but not NF-κB translocation. The induction of NF-κB seems to be much more dependent on the binding of Gads to both the YMNM and the two proline-rich motifs within the molecule. However, mutation of the final amino acid of the motif, M173, which is unable to bind PI3K but is able to bind Grb2 and Gads, gives little NF-κB or IL-2, suggesting that those Grb2 and Gads are unable to compensate for the loss of PI3K. IL-2 transcription appears to have two stages; a Y170-dependent, PI3K-dependent initial phase which allows transcription and a PI3K-independent second phase which is dependent on formation of an immune synapse, which results in enhancement of IL-2 mRNA stability. Both are required for full production of IL-2.

CD28 also contains two proline-rich motifs that are able to bind SH3-containing proteins. Itk and Tec are able to bind to the N-terminal of these two motifs which immediately succeeds the Y170 YMNM; Lck binds the C-terminal. Both Itk and Lck are able to phosphorylate the tyrosine residues which then allow binding of SH2 containing proteins to CD28. Binding of Tec to CD28 enhances IL-2 production, dependent on binding of its SH3 and PH domains to CD28 and PIP3 respectively. The C-terminal proline-rich motif in CD28 is important for bringing Lck and lipid rafts into the immune synapse via filamin-A. Mutation of the two prolines within the C-terminal motif results in reduced proliferation and IL-2 production but normal induction of Bcl-xL. Phosphorylation of a tyrosine within the PYAP motif (Y191 in the mature human CD28) forms a high affinity-binding site for the SH2 domain of the src kinase Lck which in turn binds to the serine kinase PKC-θ. [17]

Structure

The first structure of CD28 was obtained in 2005 by the T-cell biology group at the University of Oxford. [18]

The structure of the CD28 protein contains 220 amino acids, encoded by a gene consisting of four exons. It is a glycosylated, disulfide-linked homodimer of 44 kDa expressed on the cell surface. The structure contains paired domains of the V-set immunoglobulin superfamilies (IgSF). These domains are linked to individual transmembrane domains and cytoplasmic domains that contain critical signaling motifs. [19] As CTLA4, CD28 share highly similar CDR3-analogous loops. [20] In the CD28-CD80 complex, the two CD80 molecules converge such that their membrane proximal domains collide sterically, despite the availability of both ligand binding sites for CD28. [18]

CD28 family members

CD28 belongs into group members of a subfamily of costimulatory molecules that are characterized by an extracellular variable immunoglobulin-like domain. Members of this subfamily also include homologous receptors ICOS, CTLA4, PD1, PD1H, and BTLA. [21] Nevertheless, only CD28 is expressed constitutively on mouse T cells, whereas ICOS and CTLA4 are induce by T cells receptor stimulation and in response to cytokines such as IL-2. CD28 and CTLA4 are very homologous and compete for the same ligand – CD80 and CD86. [22] CTLA4 binds CD80 and CD86 always stronger than CD28, which allows CTLA4 to compete with CD28 for ligand and suppress effector T cells responses. [23] But it was shown that CD28 and CTLA4 have opposite effect on the T cells stimulation. CD28 acts as a activator and CTLA4 acts as inhibitor. [24] [25] ICOS and CD28 are also closely related genes, but they cannot substitute from one another in function. The opposing roles of CD28 and ICOS compared to CTLA4 cause that these receptors act as a rheostat for the immune response through competitive pro- and anti-inflammatory effects. [26]

As a drug target

The drug TGN1412, which was produced by the German biotech company TeGenero, and unexpectedly caused multiple organ failure in trials, is a superagonist of CD28. Unfortunately, it is often ignored that the same receptors also exist on cells other than lymphocytes. CD28 has also been found to stimulate eosinophil granulocytes where its ligation with anti-CD28 leads to the release of IL-2, IL4, IL-13 and IFN-γ. [27] [28]

It is known that CD28 and CTL4 may be critical regulators of autoimmune diseases in mouse model. [29] [30] But there is less data from patients on the role of CD28 in human diseases.

Other potential drugs in pre-clinical development are agonist CD28 aptamers with immunostimulatory properties in a mouse tumor model, [31] a monoclonal anti-CD28 Fab´ antibody FR104, [32] or an octapeptide AB103, which prevents CD28 homodimerization. [33]

Interactions

CD28 has been shown to interact with:

See also

Related Research Articles

<span class="mw-page-title-main">Cytotoxic T-lymphocyte associated protein 4</span> Mammalian protein found in humans

Cytotoxic T-lymphocyte associated protein 4, (CTLA-4) also known as CD152, is a protein receptor that functions as an immune checkpoint and downregulates immune responses. CTLA-4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells. It is encoded by the gene CTLA4 in humans.

B7 is a type of integral membrane protein found on activated antigen-presenting cells (APC) that, when paired with either a CD28 or CD152 (CTLA-4) surface protein on a T cell, can produce a costimulatory signal or a coinhibitory signal to enhance or decrease the activity of a MHC-TCR signal between the APC and the T cell, respectively. Binding of the B7 of APC to CTLA-4 of T-cells causes inhibition of the activity of T-cells.

<span class="mw-page-title-main">Fc receptor</span> Surface protein important to the immune system

In immunology, an Fc receptor is a protein found on the surface of certain cells – including, among others, B lymphocytes, follicular dendritic cells, natural killer cells, macrophages, neutrophils, eosinophils, basophils, human platelets, and mast cells – that contribute to the protective functions of the immune system. Its name is derived from its binding specificity for a part of an antibody known as the Fc region. Fc receptors bind to antibodies that are attached to infected cells or invading pathogens. Their activity stimulates phagocytic or cytotoxic cells to destroy microbes, or infected cells by antibody-mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity. Some viruses such as flaviviruses use Fc receptors to help them infect cells, by a mechanism known as antibody-dependent enhancement of infection.

Co-stimulation is a secondary signal which immune cells rely on to activate an immune response in the presence of an antigen-presenting cell. In the case of T cells, two stimuli are required to fully activate their immune response. During the activation of lymphocytes, co-stimulation is often crucial to the development of an effective immune response. Co-stimulation is required in addition to the antigen-specific signal from their antigen receptors.

<span class="mw-page-title-main">CD278</span> Protein-coding gene in the species Homo sapiens

Inducible T-cell costimulator is an immune checkpoint protein that in humans is encoded by the ICOS gene. The protein belongs to the CD28 and CTLA-4 cell-surface receptor family. These are proteins expressed on the surface of immune cells that mediate signalling between them. A surface protein, the ligand, binds specifically to its receptor on another cell, leading to a signalling cascade in that cell.

<span class="mw-page-title-main">CD80</span> Mammalian protein found in Homo sapiens

The Cluster of differentiation 80 is a B7, type I membrane protein in the immunoglobulin superfamily, with an extracellular immunoglobulin constant-like domain and a variable-like domain required for receptor binding. It is closely related to CD86, another B7 protein (B7-2), and often works in tandem. Both CD80 and CD86 interact with costimulatory receptors CD28, CTLA-4 (CD152) and the p75 neurotrophin receptor.

<span class="mw-page-title-main">CD86</span> Mammalian protein found in Homo sapiens

Cluster of Differentiation 86 is a protein constitutively expressed on dendritic cells, Langerhans cells, macrophages, B-cells, and on other antigen-presenting cells. Along with CD80, CD86 provides costimulatory signals necessary for T cell activation and survival. Depending on the ligand bound, CD86 can signal for self-regulation and cell-cell association, or for attenuation of regulation and cell-cell disassociation.

<span class="mw-page-title-main">CD134</span> Protein-coding gene in humans

Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor, is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. Expression of OX40 is dependent on full activation of the T cell; without CD28, expression of OX40 is delayed and of fourfold lower levels.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Abatacept, sold under the brand name Orencia, is a medication used to treat autoimmune diseases like rheumatoid arthritis, by interfering with the immune activity of T cells. It is a modified antibody.

In immunology, peripheral tolerance is the second branch of immunological tolerance, after central tolerance. It takes place in the immune periphery. Its main purpose is to ensure that self-reactive T and B cells which escaped central tolerance do not cause autoimmune disease. Peripheral tolerance can also serve a purpose in preventing an immune response to harmless food antigens and allergens.

<span class="mw-page-title-main">Cancer immunology</span> Study of the role of the immune system in cancer

Cancer immunology (immuno-oncology) is an interdisciplinary branch of biology and a sub-discipline of immunology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, which utilises the immune system as a treatment for cancer. Cancer immunosurveillance and immunoediting are based on protection against development of tumors in animal systems and (ii) identification of targets for immune recognition of human cancer.

<span class="mw-page-title-main">PD-L1</span> Mammalian protein found in humans

Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene.

<span class="mw-page-title-main">Programmed cell death protein 1</span> Mammalian protein found in humans

Programmed cell death protein 1(PD-1),. PD-1 is a protein encoded in humans by the PDCD1 gene. PD-1 is a cell surface receptor on T cells and B cells that has a role in regulating the immune system's response to the cells of the human body by down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity. This prevents autoimmune diseases, but it can also prevent the immune system from killing cancer cells.

<span class="mw-page-title-main">ICOSLG</span> Protein-coding gene in the species Homo sapiens

ICOS ligand is a protein that in humans is encoded by the ICOSLG gene located at chromosome 21. ICOSLG has also been designated as CD275.

<span class="mw-page-title-main">VTCN1</span> Protein-coding gene in the species Homo sapiens

V-set domain-containing T-cell activation inhibitor 1 is a protein that in humans is encoded by the VTCN1 gene.

<span class="mw-page-title-main">PDCD1LG2</span> Protein-coding gene in the species Homo sapiens

Programmed cell death 1 ligand 2 is a protein that in humans is encoded by the PDCD1LG2 gene. PDCD1LG2 has also been designated as CD273. PDCD1LG2 is an immune checkpoint receptor ligand which plays a role in negative regulation of the adaptive immune response. PD-L2 is one of two known ligands for Programmed cell death protein 1 (PD-1).

<span class="mw-page-title-main">BTLA</span> Protein-coding gene in the species Homo sapiens

B- and T-lymphocyte attenuator or BTLA is a protein that belongs to the CD28 immunoglobulin superfamily (IgSF) which is encoded by the BTLA gene located on the 3rd human chromosome. BTLA was first discovered in 2003 as an inhibitor of Th1 expansion and it became the 3rd member of the CD28 IgSF. However, its discovered ligand herpes virus entry mediator or HVEM belongs to the tumor necrosis factor receptor superfamily (TNFRSF). This finding was surprising because until the discovery of HVEM it was believed that receptors and ligands always belong to the same family.

<span class="mw-page-title-main">Immune checkpoint</span> Regulators of the immune system

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.

<span class="mw-page-title-main">CD28 family receptor</span> Group of regulatory cell surface receptors

CD28 family receptors are a group of regulatory cell surface receptors expressed on immune cells. The CD28 family in turn is a subgroup of the immunoglobulin superfamily.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000178562 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000026012 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ Gray Parkin, Kirstin; Stephan, Robert P.; Apilado, Ron-Gran; Lill-Elghanian, Deborah A.; Lee, Kelvin P.; Saha, Bhaskar; Witte, Pamela L. (2002-09-01). "Expression of CD28 by Bone Marrow Stromal Cells and Its Involvement in B Lymphopoiesis". The Journal of Immunology. 169 (5): 2292–2302. doi: 10.4049/jimmunol.169.5.2292 . ISSN   0022-1767. PMID   12193694. S2CID   22737782.
  6. ↑ Rozanski, Cheryl H.; Arens, Ramon; Carlson, Louise M.; Nair, Jayakumar; Boise, Lawrence H.; Chanan-Khan, Asher A.; Schoenberger, Stephen P.; Lee, Kelvin P. (2011-06-20). "Sustained antibody responses depend on CD28 function in bone marrow–resident plasma cells". Journal of Experimental Medicine. 208 (7): 1435–1446. doi:10.1084/jem.20110040. ISSN   1540-9538. PMC   3135367 . PMID   21690252.
  7. ↑ Venuprasad, K.; Parab, Pradeep; Prasad, D. V. R.; Sharma, Satyan; Banerjee, Pinaki P.; Deshpande, Manisha; Mitra, Dipendra K.; Pal, Subrata; Bhadra, Ranjan; Mitra, Debashis; Saha, Bhaskar (May 2001). <1536::aid-immu1536>3.0.co;2-8 "Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression". European Journal of Immunology. 31 (5): 1536–1543. doi:10.1002/1521-4141(200105)31:5<1536::aid-immu1536>3.0.co;2-8. ISSN   0014-2980. PMID   11465111. S2CID   22349635.
  8. ↑ Woerly, G.; Decot, V.; Loiseau, S.; Loyens, M.; Chihara, J.; Ono, N.; Capron, M. (September 2004). "CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate". Clinical & Experimental Allergy. 34 (9): 1379–1387. doi:10.1111/j.1365-2222.2004.02036.x. ISSN   0954-7894. PMID   15347370. S2CID   21120027.
  9. ↑ Diaz, David; Chara, Luis; Chevarria, Julio; Ubeda, Maria; Muñoz, Leticia; Barcenilla, Hugo; Sánchez, Miguel Angel; Moreno, Zaida; Monserrat, Jorge; Albillos, Agustin; Prieto, Alfredo (2011). "Loss of surface antigens is a conserved feature of apoptotic lymphocytes from several mammalian species". Cellular Immunology. 271 (1): 163–172. doi:10.1016/j.cellimm.2011.06.018. ISSN   0008-8749. PMID   21745657.
  10. ↑ Esensten, Jonathan H.; Helou, Ynes A.; Chopra, Gaurav; Weiss, Arthur; Bluestone, Jeffrey A. (May 2016). "CD28 Costimulation: From Mechanism to Therapy". Immunity. 44 (5): 973–988. doi:10.1016/j.immuni.2016.04.020. PMC   4932896 . PMID   27192564.
  11. ↑ FAGNONI, F. F.; VESCOVINI, R.; MAZZOLA, M.; BOLOGNA, G.; NIGRO, E.; LAVAGETTO, G.; FRANCESCHI, C.; PASSERI, M.; SANSONI, P. (August 1996). "Expansion of cytotoxic CD8 + CD28 − T cells in healthy ageing people, including centenarians". Immunology. 88 (4): 501–507. doi:10.1046/j.1365-2567.1996.d01-689.x. ISSN   0019-2805. PMC   1456634 . PMID   8881749.
  12. ↑ Chamberlain, Winston D.; Falta, Michael T.; Kotzin, Brian L. (March 2000). "Functional Subsets within Clonally Expanded CD8+ Memory T Cells in Elderly Humans". Clinical Immunology. 94 (3): 160–172. doi:10.1006/clim.1999.4832. PMID   10692235.
  13. ↑ Chapel, Helen (2018). Základy klinické imunologie : 6. vydání. Mansel Haeney, Siraj A. Misbah, Neil Snowden, Vojtěch Thon. Praha. ISBN   978-80-7553-396-8. OCLC   1031053171.{{cite book}}: CS1 maint: location missing publisher (link)
  14. ↑ Mou, D.; Espinosa, J.; Lo, D. J.; Kirk, A. D. (November 2014). "CD28 Negative T Cells: Is Their Loss Our Gain?: CD28 Negative T Cells". American Journal of Transplantation. 14 (11): 2460–2466. doi:10.1111/ajt.12937. PMC   4886707 . PMID   25323029.
  15. ↑ Prasad KV, Cai YC, Raab M, Duckworth B, Cantley L, Shoelson SE, Rudd CE (March 1994). "T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif". Proceedings of the National Academy of Sciences of the United States of America. 91 (7): 2834–8. Bibcode:1994PNAS...91.2834P. doi: 10.1073/pnas.91.7.2834 . PMC   43465 . PMID   8146197.
  16. ↑ Schneider H, Cai YC, Prasad KV, Shoelson SE, Rudd CE (April 1995). "T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras". European Journal of Immunology. 25 (4): 1044–50. doi:10.1002/eji.1830250428. PMID   7737275. S2CID   23540587.
  17. ↑ Kong KF, Yokosuka T, Canonigo-Balancio AJ, Isakov N, Saito T, Altman A (October 2011). "A motif in the V3 domain of the kinase PKC-θ determines its localization in the immunological synapse and functions in T cells via association with CD28". Nature Immunology. 12 (11): 1105–12. doi:10.1038/ni.2120. PMC   3197934 . PMID   21964608.
  18. 1 2 Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, et al. (March 2005). "Crystal structure of a soluble CD28-Fab complex". Nature Immunology. 6 (3): 271–9. doi:10.1038/ni1170. PMID   15696168. S2CID   23630078.
  19. ↑ Carreno BM, Collins M (April 2002). "The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses". Annual Review of Immunology. 20 (1): 29–53. doi:10.1146/annurev.immunol.20.091101.091806. PMID   11861596.
  20. ↑ Zhang X, Schwartz JC, Almo SC, Nathenson SG (March 2003). "Crystal structure of the receptor-binding domain of human B7-2: insights into organization and signaling". Proceedings of the National Academy of Sciences of the United States of America. 100 (5): 2586–91. Bibcode:2003PNAS..100.2586Z. doi: 10.1073/pnas.252771499 . PMC   151384 . PMID   12606712.
  21. ↑ Chen L, Flies DB (April 2013). "Molecular mechanisms of T cell co-stimulation and co-inhibition". Nature Reviews. Immunology. 13 (4): 227–42. doi:10.1038/nri3405. PMC   3786574 . PMID   23470321.
  22. ↑ Linsley PS, Clark EA, Ledbetter JA (July 1990). "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1". Proceedings of the National Academy of Sciences of the United States of America. 87 (13): 5031–5. Bibcode:1990PNAS...87.5031L. doi: 10.1073/pnas.87.13.5031 . PMC   54255 . PMID   2164219.
  23. ↑ Engelhardt JJ, Sullivan TJ, Allison JP (July 2006). "CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism". Journal of Immunology. 177 (2): 1052–61. doi: 10.4049/jimmunol.177.2.1052 . PMID   16818761. S2CID   7990944.
  24. ↑ Krummel MF, Allison JP (August 1995). "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation". The Journal of Experimental Medicine. 182 (2): 459–65. doi:10.1084/jem.182.2.459. PMC   2192127 . PMID   7543139.
  25. ↑ Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. (August 1994). "CTLA-4 can function as a negative regulator of T cell activation". Immunity. 1 (5): 405–13. doi:10.1016/1074-7613(94)90071-x. PMID   7882171.
  26. ↑ Linterman MA, Rigby RJ, Wong R, Silva D, Withers D, Anderson G, et al. (February 2009). "Roquin differentiates the specialized functions of duplicated T cell costimulatory receptor genes CD28 and ICOS". Immunity. 30 (2): 228–41. doi: 10.1016/j.immuni.2008.12.015 . PMID   19217324.
  27. ↑ Woerly G, Roger N, Loiseau S, Dombrowicz D, Capron A, Capron M (August 1999). "Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes". The Journal of Experimental Medicine. 190 (4): 487–95. doi:10.1084/jem.190.4.487. PMC   2195599 . PMID   10449520.
  28. ↑ Woerly G, Lacy P, Younes AB, Roger N, Loiseau S, Moqbel R, Capron M (October 2002). "Human eosinophils express and release IL-13 following CD28-dependent activation". Journal of Leukocyte Biology. 72 (4): 769–79. doi: 10.1189/jlb.72.4.769 . PMID   12377947. S2CID   10820672.
  29. ↑ Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA (April 2000). "B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes". Immunity. 12 (4): 431–40. doi: 10.1016/s1074-7613(00)80195-8 . PMID   10795741.
  30. ↑ Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (November 1995). "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4". Immunity. 3 (5): 541–547. doi: 10.1016/1074-7613(95)90125-6 . ISSN   1074-7613. PMID   7584144. S2CID   46680106.
  31. ↑ Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, et al. (June 2013). "CD28 aptamers as powerful immune response modulators". Molecular Therapy: Nucleic Acids. 2 (6): e98. doi:10.1038/mtna.2013.26. PMC   3696906 . PMID   23756353.
  32. ↑ Poirier N, Mary C, Dilek N, Hervouet J, Minault D, Blancho G, Vanhove B (October 2012). "Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody". American Journal of Transplantation. 12 (10): 2630–40. doi: 10.1111/j.1600-6143.2012.04164.x . PMID   22759318. S2CID   715661.
  33. ↑ Mirzoeva S, Paunesku T, Wanzer MB, Shirvan A, Kaempfer R, Woloschak GE, Small W (2014-07-23). "Single administration of p2TA (AB103), a CD28 antagonist peptide, prevents inflammatory and thrombotic reactions and protects against gastrointestinal injury in total-body irradiated mice". PLOS ONE. 9 (7): e101161. Bibcode:2014PLoSO...9j1161M. doi: 10.1371/journal.pone.0101161 . PMC   4108308 . PMID   25054224.
  34. ↑ Ellis JH, Ashman C, Burden MN, Kilpatrick KE, Morse MA, Hamblin PA (June 2000). "GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28". Journal of Immunology. 164 (11): 5805–14. doi: 10.4049/jimmunol.164.11.5805 . PMID   10820259. S2CID   25739159.
  35. ↑ Okkenhaug K, Rottapel R (August 1998). "Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction". The Journal of Biological Chemistry. 273 (33): 21194–202. doi: 10.1074/jbc.273.33.21194 . PMID   9694876. S2CID   39280280.
  36. ↑ Nunès JA, Truneh A, Olive D, Cantrell DA (January 1996). "Signal transduction by CD28 costimulatory receptor on T cells. B7-1 and B7-2 regulation of tyrosine kinase adaptor molecules". The Journal of Biological Chemistry. 271 (3): 1591–8. doi: 10.1074/jbc.271.3.1591 . PMID   8576157. S2CID   37740924.
  37. ↑ Pagès F, Ragueneau M, Klasen S, Battifora M, Couez D, Sweet R, et al. (April 1996). "Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association". The Journal of Biological Chemistry. 271 (16): 9403–9. doi: 10.1074/jbc.271.16.9403 . PMID   8621607. S2CID   12566111.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.